Dear Secretary Sebelius:
I was disappointed to read your
letter regarding the media report published in
Reuters yesterday as well as your assertion that
WellPoint "deliberately works to deny coverage for
women diagnosed with breast cancer." Both your
statement and Mr. Waas' piece are inaccurate and
grossly misrepresent WellPoint's efforts to help
prevent, detect, and treat the 1 in 8 of our 34
million members nationwide affected by breast
cancer.
To be absolutely clear, WellPoint
does not single out women with breast cancer for
rescission. Period.
I am confident you read the
detailed statement WellPoint issued yesterday
highlighting the many factual inaccuracies and
unfounded opinions written by Mr. Waas. In light of
the facts we have presented, I am disappointed by
your letter and the needless anxiety and fear it has
raised amongst our members and associates. Our
statement is available to the public at
www.wellpoint.com. Rather than re-state those
details here, I would like to describe a few of the
many WellPoint breast cancer prevention and
treatment programs that serve as facts to the
contrary of Mr. Waas' article and your letter.
WellPoint's more than 3,000
nurses and clinical associates work each day to
encourage detection of breast cancer at its earliest
stages and to ensure our members are receiving the
best breast cancer treatments available. This is
neither rhetoric nor exaggeration, as their outreach
has increased early breast screenings by nearly
300,000 WellPoint members since 2007. We track this
and 39 other health measures through our annual
Member Health Index, to which a portion of each
WellPoint associates' annual incentive compensation
is tied.
WellPoint also covers mammograms
for members ages 40 or above, 10 years earlier than
the guidelines published by the U.S. Preventive
Services Task Force. We made this policy decision
because we know that early detection is the key to
survival, with 5-year survival rates of nearly 100%
when diagnosed at stages 0 or 1. This also reduces
health care costs for the entire system, by avoiding
the approximately 10-fold increase in costs
associated with treatment beginning after stage 3.
Through research we conducted
with the American Cancer Society and Amgen, we
discovered our African-American members in Georgia
were 50% more likely to be diagnosed at a later
stage of breast cancer than Caucasians, and were
less likely to receive state-of-the art hormone
therapy treatment. The research was published in the
January edition of "Cancer", the nation's most
prestigious and authoritative journal on cancer
research and is being translated into programs to
better educate members and physicians by our Racial
and Ethnic Health Inequalities team. I would also
like to point out that in 2008, WellPoint was
awarded the Corporate Leadership Award by the
Congressional Black Caucus in recognition of our
preliminary, yet groundbreaking work to reduce
health inequalities in the treatment of breast
cancer.
We have been very happy to see
that as detection and treatment of breast cancer
improves, so too does survivorship. This is why we
worked with the National Coalition for Cancer
Survivorship, Genentech, and the UCLA Cancer
Survivorship Center to design "The Journey Forward,"
http://www.journeyforward.org/. This program helps
physicians and patients to make the transition from
oncology care back to primary care and ensures
follow-up visits are scheduled, necessary
medications are picked up, and survivors get the
necessary support to remain cancer-free.
These are just a few of the
programs we have in place to address this disease,
and this response does not include the countless
programs supported by the WellPoint Foundation. Our
giving and participation in cancer programs earned
us the American Cancer Society's 2009 Corporate
Impact Award, their highest level of annual
corporate recognition.
Madame Secretary, a three-story
pink ribbon hangs in the lobby of our Indianapolis
headquarters for many reasons. It provides meaning,
motivation, and purpose for our company, our
associates and their families. There is arguably no
American that does not have a mother, grandmother,
sister, or friend who has been affected by breast
cancer, and I am no exception. I understand that
passions run high when discussing health reform.
Breast cancer is a devastating illness and should
not be politicized. I proudly stand behind our
company and our associates and all they do to
support WellPoint's programs that improve the
quality of health care for our members with breast
cancer.
I request the opportunity to meet
with you personally to further clarify the erroneous
issues presented in your letter and discuss
WellPoint's programs with you in greater detail. Our
nation's fight against breast cancer demands that we
work together as one.
Sincerely,
Angela F. Braly
AFB:LH